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ABSTRACT
Objective: Nerve-sparing radical hysterectomy (NSRH) was introduced with the aim to 
reduce pelvic dysfunctions related to conventional radical hysterectomy (RH). Here, we 
sought to assess the effectiveness and safety of NSRH in a relatively large number of the 
patients of cervical cancer (CC) patients undergoing either primary surgery or neoadjuvant 
chemotherapy (NACT) followed by surgery.
Methods: Outcomes of consecutive patients undergoing NSRH and of a historical cohort of 
patients undergoing conventional RH were retrospectively reviewed.
Results: This study included 325 (49.8%) and 327 (50.2%) undergoing NSRH and RH, 
respectively. Via a multivariable model, nodal status was the only factor predicting for DFS 
(hazard ratio [HR]=2.09; 95% confidence interval [CI]=1.17–3.73; p=0.01). A trend towards 
high risk of recurrence was observed for patients affected by locally advanced cervical cancer 
(LACC) undergoing NACT followed by surgery (HR=2.57; 95% CI=0.95–6.96; p=0.06). Type 
of surgical procedures (NSRH vs. RH) did not influence risk of recurrence (p=0.47). Similarly, 
we observed that the execution of NSRH rather than RH had not a detrimental effect on OS 
(HR=1.19; 95% CI=0.16–9.01; p=0.87). Via multivariable model, no factor directly correlated 
with OS. No difference in early complication rates was observed between the study groups. 
Conversely, a significant higher number of late complications was reported in RH versus 
NSRH groups (p=0.02).
Conclusions: Our data suggested that NSRH upholds effectiveness of conventional RH, 
without increasing recurrence and complication rates but improving pelvic dysfunction rates.
Keywords: Uterine Cervical Neoplasms; Complications; Hysterectomy; Surgery; Survival
INTRODUCTION
Cervical cancer (CC) is currently the fourth most common malignant disease of women 
worldwide; according to GLOBOCAN series of the International Agency for Research on 
Cancer, an estimated 560,505 new cases of CC were diagnosed in 2012, and approximately 
285,000 deaths due to this type of tumor were recorded during the same period [1].
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Surgical treatment, including radical hysterectomy (RH) with or without bilateral salpingo-
oophorectomy and pelvic lymphadenectomy +/− para-aortic lymphadenectomy, is the 
gold standard for women with early stage CC. Furthermore, although radio-chemotherapy 
represents the standard of care for patients affected by locally advanced cervical cancer 
(LACC), neoadjuvant chemotherapy (NACT) followed by radical surgery represents a safe 
alternative [2].
Ideally, surgical treatment of CC should guarantee maximal oncological disease control while 
minimizing early and late morbidity. Since the first description of the RH by Wertheim in 
1898, several technical modifications have been developed with the aim of decreasing the rate 
of intra-operative complications and postoperative pelvic dysfunctions. In this scenario, the 
concept of preservation of autonomic nerves during RH has become the standard in many 
gynecological oncologic centers [3]. Nerve-sparing radical hysterectomy (NSRH) was firstly 
introduced and subsequently sharpened by the Japanese school [4,5]. Available studies have 
shown the benefits of NSRH in terms of functional outcomes (bladder, bowel, and sexual 
function) [6-8], while weaker evidence is available on the oncologic outcomes of this surgical 
procedure. In fact, a recent systematic review underlines that most of the trials lacked a 
control group, had small sample size, and had short follow-up intervals [9].
Therefore, the current retrospective study compared the effectiveness and safety of NSRH 
with conventional RH in a relatively large number of the patients of CC patients undergoing 
either primary surgery or NACT followed by surgery.
MATERIALS AND METHODS
A large institutional prospectively collected database, including CC patients between 1980 and 
1995, and between 2001 and 2015 was retrospectively reviewed, searching records of women 
who underwent either primary radical surgery or NACT followed by radical surgery. The 
patients submitted to surgery between 1996 and 2000 were not considered in this study because 
in this period, according to protocol, we did not perform type III RH. All patients gave consent 
for the use of personal information for health research. The Institutional Review Board (IRB) of 
National Cancer Institute – Milan approved this study (approval number: INT-006812).
Inclusion criteria were histologically diagnosed CC, type C (both C1 and C2) RH according to 
Querleu-Morrow classification [10], and age more than 18 years.
Exclusion criteria were: other metachronous or synchronous neoplasia; history of 
preoperative urinary, intestinal, or sexual dysfunctions; presence of other severe 
comorbidities; previous pelvic surgery (all but cesarean section); presence of psychiatric 
disease or any condition precluding the acquisition of written informed consent.
For the purposes of the study, patients were distinguished in 2 groups: women undergoing 
type C1 NSRH and those undergoing conventional type C2 RH.
The primary outcome of this study was to evaluate the 5-year oncologic outcomes, disease-
free survival (DFS) and overall survival (OS) between the study groups. Secondary outcome 
was to compare the rate and the type of recurrences rate. Tertiary outcome was to assess the 
rate of early and late complications/dysfunctions between the study groups.
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Patients were preoperatively assessed with complete physical and gynecologic examination, 
routine blood and urine analysis, chest radiograph, and magnetic resonance imaging. 
Cystoscopy, rectoscopy, or computed tomography was performed only when clinically 
indicated. The stage of the disease was determined by the International Federation of 
Gynecology and Obstetrics (FIGO) staging system [11].
NACT consisted in 3 to 4 cycles of platinum-based chemotherapy. Since 2001, all patients 
with FIGO stage IB2, IIA2 and IIB underwent NACT. All patients included in the study 
underwent radical surgery including RH with or without bilateral salpingo-oophorectomy and 
pelvic lymphadenectomy +/− para-aortic lymphadenectomy. Type C1 RH was performed as 
previously described [12-14]. Two experienced surgeons (more than 500 radical hysterectomies 
performed) in gynecologic oncology (F.R. and A.D.) performed all surgical procedures.
Pelvic lymphadenectomy consisted of total removal of all lymph fatty tissue around pelvic 
vessels and obturator fossae. Para-aortic lymphadenectomy was performed only when pelvic 
lymph node was positive for the presence of metastases in the iliac area on frozen section.
Pathologic evaluation included histological type, depth of cervical stromal infiltration, 
infiltration of parametrium and resection margins, vaginal involvement, lymph vascular 
space invasion (LVSI), tumor diameter, number of pelvic lymph nodes, and number of lymph 
node metastases.
In group RH, in case of positive lymph nodes, parametrial or/and vaginal involvement, or 
positive surgical resection margins (<5 mm), presence of at least 2 cervical risk factors after 
RH according to Sedlis criteria [15], patients underwent adjuvant radiotherapy, whereas, 
the presence of LVSI alone was not considered sufficient to receive adjuvant therapy. In 
group NSRH, in case of positive lymph nodes, parametrial or/and vaginal involvement, or 
positive surgical resection margins (<5 mm) patients underwent adjuvant radiotherapy. In 
the RH group, according to that period's protocol, all patients were submitted to adjuvant 
brachytherapy.
Recurrences were diagnosed during regular follow-up visits and confirmed by computed 
tomographic and/or magnetic resonance imaging scans. Whenever possible, histologic or 
cytologic confirmation was obtained. Local recurrences were defined as vaginal recurrences, 
pelvic recurrences, or pelvic lymph node metastases.
The following medical, perioperative and pathologic information were obtained from the 
database review: age, body mass index (BMI), parity, operative time, estimated blood loss, 
intraoperative complications, number of perioperative blood transfusions, hospital stay, 
early and late postoperative complications, pain evaluation using a visual analogue scale, 
resumption of bladder function (day of urinary catheter removal with urinary residual 
<100 cc after first spontaneous micturition), FIGO stage, histopathologic subtype, number 
and disease status of lymph nodes removed, follow-up time, DFS, OS, and locoregional 
recurrence (LRR). For OS, event times were computed as the interval between the date of 
surgery and the date of death for any cause, with censoring at the date of last follow-up 
for alive patients. For DFS, event times were computed as the interval between the date of 
surgery and the date of first relapse or death for any cause, with censoring at the date of 
last follow-up for event-free subjects. For LRR, event times were computed as the interval 
between the date of surgery and the date of local relapse as first event, censoring at the date 
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of last follow-up for event-free patients, and considering as competing events vaginal relapse, 
distant relapse, and death, whichever occurred first. Post-operative complications were 
arbitrarily distinguished in early (those occurring in a period of time ≤60 days) and late (those 
occurring in a period of time >60 days) complications.
1. Statistical analysis
Data are summarized using basic descriptive statistics. The normal distribution of continuous 
variable data was evaluated with the Kolmogorov-Smirnov test. Categorical variables were 
analyzed using the χ2 test. Continuous variables, before and after treatment, were analyzed by 
using the paired t-test and the Wilcoxon rank sum test accordingly to data distribution.
Survival outcomes were evaluated with both Kaplan-Meier and Cox models. Hazard ratio 
(HR) and 95% confidence intervals (CIs) were calculated for each comparison. Univariate 
and multivariate analysis were performed when appropriate. All covariates with a p value less 
than 0.20, based on univariate analysis were included in the multivariate model. All p values 
were 2-sided. Statistical analysis was performed using GraphPad Prism version 6.0 for Mac 
(GraphPad Software, San Diego, CA, USA) and IBM-Microsoft SPSS version 20.0 for Mac 
(SPSS Science, Chicago, IL, USA). The p values <0.05 were statistically significant.
RESULTS
The study included 652 patients: 325 (49.8%) and 327 (50.2%) undergoing NSRH and RH, 
respectively. The median (range) follow-up was 38 months (range, 1–131 months) and 123 
months (range, 1–338 months) for NSRH and RH group, respectively. Main characteristics 
of the 2 study groups are shown in Table 1. No significant difference in the histology was 
reported between the 2 study groups. Most patients had squamous cell carcinoma, 74.5% and 
87.8% for NSRH and RH, respectively, while for adenocarcinoma, these figures were 15.7% 
and 7.4%. The pathological analysis showed that the rate of positive pelvic nodes was similar 
between NSRH (20.9%) and RH (19.9%) groups. No significant difference in the median 
(range) number of pelvic/para-aortic lymph nodes dissected was reported between NSRH 
(37.5 [12–80]) and RH (36 [10–105]) groups (p=0.546). The large majority of patients included 
in the NSRH group (89%) received NACT in comparison with RH group (21.1%; p<0.01).
1. Recurrences and survival outcomes
Considering all the patients, 5-year DFS (Fig. 1A) was significantly inferior in NSRH group 
(77.7%) compared with RH group (84.5%; log-rank=5.394; p=0.02); 5-year OS (Fig. 1B) was 
90.4% in NSRH group and 84.9% in RH group (log-rank=2.214; p=0.13). Interestingly, 
considering only patients who received NACT, 5-year DFS (Fig. 1C) in NSRH and RH groups 
were 76.6% and 75.6% (log rank=0.000; p=0.98), respectively; 5-year OS (Fig. 1D) was 89.3% 
in NSRH group and 79.4% in RH group (log rank=3.664; p=0.06).
Via a multivariable model (Table 2), it was observed that nodal status is the only factor 
predicting for DFS (HR=2.09; 95% CI=1.17–3.73; p=0.01). Type of surgical procedures 
(NSRH vs. RH) did not influence risk of recurrence (p=0.47). The execution of NSRH did not 
correlate with an increased risk of developing local (HR=1.32; 95% CI=0.58–3.01; p=0.50), 
regional (HR=1.26; 95% CI=0.41–3.81; p=0.67) and distant (HR=0.34; 95% CI=0.08–1.35; 
p=0.12) recurrences. Via multivariable model (Table 3), no factor directly correlated with 
OS. Furthermore, we observed that the execution of NSRH rather than RH had not a 
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Table 1. Main characteristics of the study population
Characteristics Group NSRH (n=325) Group RH (n=327) p
Age (yr) 49 (26–77) 46 (22–75)
BMI 0.85
Normal (< 30) 258 (79.4) 256 (78.3)
Obese (≥30 and <35) 24 (7.4) 28 (8.5)
Severely obese (≥35) 12 (3.7) 15 (4.6)
Missing data 31 (9.5) 28 (8.6)
Histology <0.01
Squamous cell 242 (74.5) 287 (87.8)
Adenocarcinoma 51 (15.7) 24 (7.4)
Other type 19 (5.8) 4 (1.2)
Missing data 13 (4.0) 12 (3.6)
Grade <0.01
1 14 (4.3) 8 (2.5)
2 98 (30.2) 23 (7.0)
3 187 (57.5) 23 (7.0)
Missing data 26 (8.0) 273 (83.5)
FIGO stage <0.01
IA2 1 (0.3) 2 (0.6)
IB1 51 (15.7) 173 (52.9)
IB2 88 (27.1) 83 (25.4)
IIA 57 (17.5) 44 (13.5)
IIB 128 (39.4) 25 (7.6)
LVSI <0.01
No 134 (41.2) 6 (1.8)
Yes 178 (54.8) 53 (16.2)
Missing data 13 (4.0) 268 (82.0)
Parametrium <0.01
Negative 279 (85.8) 302 (92.4)
Positive 46 (14.2) 25 (7.6)
Vagina <0.01
Negative 254 (78.2) 289 (88.4)
Positive 71 (21.8) 38 (11.6)
Lymph node 0.74
Negative 257 (79.1) 262 (80.1)
Positive 68 (20.9) 65 (19.9)
Pelvic lymphadenectomy 1.00
Performed 324 (99.7) 325 (99.4)
Sampling 1 (0.3) 2 (0.6)
Not performed 0 (0) 0 (0)
Para-aortic lymphadenectomy <0.01
Performed 31 (9.6) 94 (28.8)
Sampling 17 (5.2) 2 (0.6)
Not performed 277 (85.2) 231 (70.6)
Salpingo-oophorectomy 0.67
No 112 (34.5) 91 (27.8)
Yes 213 (65.5) 236 (72.2)
Depth of stromal invasion in the specimen (mm) <0.01
<3 111 (34.2) 62 (19.0)
3–10 106 (32.6) 151 (46.2)
>10 108 (33.2) 114 (34.8)
NACT <0.01
No 28 (8.6) 258 (78.9)
Yes 295 (89.0) 69 (21.1)
Post-surgical therapy <0.01
None 167 (51.4) 31 (9.5)
Radiotherapy 83 (25.5) 291 (89.0)
Chemotherapy 24 (7.4) 4 (1.2)
Chemoradiotherapy 51 (15.7) 1 (0.3)
Data are presented as median (range) or number (percentage).
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymph vascular space invasion; NACT, neoadjuvant chemotherapy; NS, 
not significant; NSRH, nerve-sparing radical hysterectomy; RH, radical hysterectomy.
detrimental effect on OS (HR=1.19; 95% CI=0.16–9.01; p=0.87). Furthermore, no difference 
either in the rate or in the type of recurrence was reported between the two study groups 
(Supplementary Table 1).
2. Surgery related outcomes
A detailed presentation of surgical characteristics is described in Table 4. No statistical 
difference between the two study groups was observed in the operative time. Blood loss as 
well the number of blood units transfused was superior in patients of RH group than those 
of NSRH group. Median (range) hospital stay was shorter for women of NSRH group (7 
[3-16]) compared with those of RH group (18 [3-131]; p<0.01). Higher rates of intraoperative 
complications were reported in RH group (n=65) versus NSRH group (n=41; p=0.01). No 
difference in early complication rates was observed between the 2 study groups. Conversely, 
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Fig. 1. Five-year DFS and OS in the study population and in the NACT subgroup of patients (time is expressed in months). (A) 5-year DFS in NSRH and RH groups. 
(B) 5-year OS in NSRH and in RH groups. (C) 5-year DFS considering only patients who received NACT in NSRH and RH groups. (D) 5-year OS considering only 
patients who received NACT in NSRH and RH groups. 
DFS, disease-free survival; NACT, neoadjuvant chemotherapy; NSRH, nerve-sparing radical hysterectomy; OS, overall survival; RH, radical hysterectomy.
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Table 2. Factors influencing DFS
Characteristics Univariate analysis for DFS p Multivariate analysis for DFS p
Age (yr) 0.99 (0.97–1.01) 0.35 - -
BMI (kg/m2) 1.04 (0.69–1.55) 0.83 - -
Parity 0.96 (0.76–1.21) 0.74 - -
Histology 0.37 -
Squamous cell Reference
Non-squamous cell 0.62 (0.21–1.77) -
FIGO grade <0.01 0.25
Grade 1&2 Reference Reference
Grade 3 1.97 (1.27–3.07) 1.36 (0.81–2.28)
LVSI 0.02 0.50
No Reference Reference
Yes 1.83 (1.09–3.09) 1.23 (0.67–2.23)
FIGO stage at presentation <0.01 0.06
Early stage Reference Reference
Locally advance stage 1.78 (1.20–2.64) 2.57 (0.95–6.96)
Nerve sparing 0.02 0.47
No Reference Reference
Yes 1.53 (1.05–2.22) 0.67 (0.23–2,00)
Parametrial involvement <0.01 0.25
No Reference Reference
Yes 1.53 (1.05–4.03) 1.46 (0.77–2.80)
Vaginal involvement <0.01 -
No Reference Reference
Yes 2.83 (1.91–4.20) 1.30 (0.73–2.33)
Lymph nodes positivity <0.01 0.01
No Reference Reference
Yes 3.38 (2.35–4.88) 2.09 (1.17–3.73)
Data are presented as HR (95% CI).
BMI, body mass index; DFS, disease-free survival; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymph vascular space invasion.
Table 3. Factors influencing OS
Characteristics Univariate analysis for OS p Multivariate analysis for OS p
Age (yr) 1.01 (0.99–1.02) 0.36 - -
BMI (kg/m2) 1.03 (0.79–1.25) 0.76 - -
Parity 0.95 (0.89–1.11) 0.89 - -
Histology 0.01 0.86
Squamous cell Reference Reference
Non-squamous cell 0.33 (0.14–7.60) 0.27 (0.63–1.20)
FIGO grade <0.01 0.88
Grade 1&2 Reference Reference
Grade 3 2.86 (1.38–5.97) 2.53 (0.87–7.34)
LVSI <0.01 0.80
No Reference Reference
Yes 5.03 (1.78–14.1) 2.77 (0.89–8.64)
FIGO stage at presentation 0.68 -
Early stage Reference
Locally advance stage 1.09 (0.72–1.64) -
Nerve sparing 0.06 0.87
No Reference Reference
Yes 0.66 (0.40–1.07) 1.19 (0.16–9.01)
Parametrial involvement 0.02 0.79
No Reference Reference
Yes 1.92 (1.07–3.47) 1.14 (0.42–3.09)
Vaginal involvement <0.01 0.49
No Reference Reference
Yes 2.18 (1.35–3.53) 1.37 (0.57–3.29)
Lymph nodes positivity <0.01 0.10
No Reference Reference
Yes 3.05 (1.35–3.53) 2.05 (0.87–4.84)
Data are presented as HR (95% CI).
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymph vascular space invasion; OS, overall survival.
a significant higher number of late complications was reported in RH group (n=37) versus 
NSRH group (n=20; p=0.02).
DISCUSSION
The current study investigated the effectiveness and safety of NSRH with RH in a relatively 
large number of the patients of CC patients undergoing either primary surgery or NACT 
followed by surgery. It was reported no difference in 5-year OS was significantly between RH 
and NSRH groups, while 5-year DFS was superior in RH group compared with NSRH group. 
However, this finding is not surprising due to the higher number of patients of NSRH group 
with LACC and treated with NACT, and to the larger use of adjuvant radiotherapy in NSRH 
group. In fact, when considering only patients receiving NACT no difference in both 5-year 
DFS and OS was reported. Interestingly, while no difference has been reported in the rate 
of early complications between 2 study groups, a higher number of late complications was 
experienced by patients of RH group, mainly due to lymphatic complications or intestinal 
ileus. Patients belonging to this group were operated in an older period of time compared 
with patients of NSRH group; therefore, the use of vascular clips and energy coagulation was 
superior in NSRH group and this may justify the higher number of lymphatic complications 
in RH group. In addition, it is well known that the autonomic nerves innervate the bowel and 
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Table 4. Intraoperative and postoperative characteristics
Characteristics Group NSRH (n=325) Group RH (n=327) p
Operative time (min) 240 (138–370) 240 (120–365) 0.42
Blood loss (mL) 300 (50–2,500) 600 (100–3,000) <0.01
Number of blood units transfused 1 (0–5) 2 (0–10) <0.01
Hospital stay (day) 7 (3–16) 18 (7–131) <0.01
Number of intraoperative complications* 5 (1.5) 11 (3.4) 0.13
Bladder function <0.01
No recovery 16 (4.9) 43 (13.1)
Recovery 309 (95.1) 275 (84.1)
Missing data 0 (0) 9 (2.8)
Presence of postoperative complications (grade ≥3)† 41 (12.6) 65 (19.8) 0.01
Total early postoperative complications (grade ≥3) 21 (6.5) 28 (8.6) 0.40
Early postoperative complications (grade ≥3) 0.04
Lymphatic (lymphocyst-lymphorrhea) 3 (0.9) 13 (4.0)
Hemorrhage/bleeding 9 (2.8) 2 (0.6)
Intestinal ileus 1 (0.3) 3 (0.9)
Urological 2 (0.6) 3 (0.9)
Thromboembolism 0 (0) 2 (0.6)
Need for another surgery 1 (0.3) 2 (0.6)
Infection 1 (0.3) 2 (0.6)
Neurologic 3 (0.9) 1 (0.3)
Voiding 1 (0.3) 0 (0)
More than one complication 0 (0) 0 (0)
Total late postoperative complications (grade ≥3) 20 (6.2) 37 (11.3) 0.02
Late postoperative complications (grade ≥3) 0.05
Lymphatic (lymphocyst-lymphorrhea) 6 (1.8) 12 (3.7)
Impaired bowel function 0 (0) 9 (2.8)
Urological 7 (2.2) 6 (1.8)
Need for another surgery 4 (1.2) 4 (1.2)
Infection 1 (0.3) 4 (1.2)
Voiding 1 (0.3) 2 (0.6)
More than one complication 1 (0.3) 0 (0)
Data are presented as median (range) or number (percentage).
*According to the Common Terminology Criteria for Adverse Events (CTCAE); †some patients had both early and late postoperative complications.
that the damage to these nerves in the pelvis can lead to diarrhoea or constipation [12,16,17], 
thus explaining why more patients experienced impaired bowel function in RH group.
Different trials have compared class II RH with class III NSRH showing similar results in terms 
of bladder function, quality of life, and oncological outcomes. However, only few studies 
have investigated the outcomes of type C1 NSRH compared with conventional type C2 RH in 
the treatment of CC [14,18]. Our previous research included a total of 496 patients, of whom 
185 patients were treated with type C1 NSRH and 311 patients with type C2 RH with a median 
follow-up of 93 months (42 and 159 months for the NSRH and RH groups, respectively). This 
study demonstrated that the oncologic results and relapse rates were comparable between 
the 2 study groups. Bladder function and postoperative complications rate were significantly 
better in the NSRH than in RH group [14]. These findings are confirmed by the current study, 
which was conducted in a substantially enlarged study population, supporting the role of 
nerve-sparing technique. More recently a randomized controlled trial (RCT) was conducted 
to evaluate the efficacy of type C1 NSRH in preserving bladder function and its oncologic 
safety in the treatment of CC. Ninety-two patients with CC stage IA2 to IIA were randomized 
to surgical treatment with type C2 RH (N=44) or type C1 NSRH (n=48), and 86 patients finally 
included in the analysis. This trial demonstrated no difference in 10-year DFS between the RH 
group (94.9%) and NSRH group (92.4%). Furthermore, volume of residual urine and bladder 
compliance were significantly deteriorated at 12 months after RH, while all parameters of 
urodynamic study were recovered no later than 3 months after NSRH. This study is the only 
available RCT investigating the issue of type C1 NSRH versus conventional type C2 RH. However, 
from a merely statistical point of view, it is significantly underpowered to assess oncologic 
outcomes. Indeed, a recent systematic review on this issue by Basaran and colleagues [9] has 
been underlined this concept. In their paper, the Authors calculated that the number of patients 
needed to prove non-inferiority of NSRH to RH with regard to recurrence would be between 
4,300 and 1,000 depending on the expected risk of recurrence (5% and 20%, respectively) 
[9]. In this view, we deem that our study provides important data due to the large number of 
patients included; however, we acknowledge that the main limitations of the current work are 
represented by the inherent biases of the retrospective, single centre study design. Another 
limitation of this study is that standardized questionnaires and/or urodynamic study were not 
used to evaluate bladder function before and after surgery, thus limiting the assessment of this 
specific outcome. Finally, the significant difference in length of follow-up between the two 
study groups prevents us to show the long-term follow-up (10 years) of the patients.
In conclusion, this study supports the efficacy and safety of NSRH for the treatment of 
CC patients. NSRH seems superior to RH, NSRH correlates with lower morbidity rate 
and similar oncologic outcomes than RH. Although the retrospective design of the study, 
we deem that our findings may be useful to provide a more detailed preoperative and 
postoperative counselling to the patients. However, well-designed, large-scale prospective 
non-inferiority trials are strongly required to confirm these results.
SUPPLEMENTARY MATERIAL
Supplemental Table 1
Rate and type of recurrences
Click here to view
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